藥明康德(02359.HK)上半年度業績快報:歸母淨利潤同比增長約62.49%
格隆匯 7 月 20日丨藥明康德(02359.HK)發佈截至2020年6月30日止六個月業績快報公告,報告期間,公司逐步從新型冠狀病毒肺炎疫情中恢復過來,並在第二季度實現強勁增長。與2019年第二季度相比,公司營業收入預計同比增長約29.41%,歸屬於母公司持有者的淨利潤預計同比增長約111.46%,基本每股收益預計同比增長約110.34%。
公司2020年上半年度整體營業收入預計同比增長約22.68%,歸屬於母公司持有者的淨利潤預計同比增長約62.49%,基本每股收益預計同比增長約63.04%。
在公司美國區實驗室服務的收入和利潤因為2020年第二季度美國新冠疫情加重受到較大負面影響的情況下,公司中國區實驗室服務及CDMO(合同開發生產服務)服務分部已全面運營,且海外客户的需求增加。得益於強勁需求、產能利用及經營效率的提升,集團於第二季度實現營業收入強勁增長。同時,公司的臨牀CRO(合同研究服務)及SMO(現場管理服務)服務也處於逐步恢復中。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.